Literature DB >> 15128778

Autoreactive T cells in healthy individuals.

Nancy A Danke1, David M Koelle, Cassian Yee, Sucheta Beheray, William W Kwok.   

Abstract

The presence of autoreactive CD4(+) T cells in the peripheral blood of healthy human subjects was investigated after removal of CD4(+)CD25(+) regulatory T cells (Treg). CD4(+) T cells that were directed against the type 1 diabetes-associated autoantigen glutamic acid decarboxylase 65, the melanocyte differentiation Ag tyrosinase, and the cancer/testis tumor Ag NY-ESO-1 were readily derived from PBMC of healthy individuals. These autoreactive T cells could be visualized, using Ag-specific class II tetramer reagents, in the peripheral blood of most individuals examined. Addition of CD4(+)CD25(+) Treg back to the CD4(+)CD25(-) population suppressed the expansion of the autoreactive T cells. Autoreactive T cells were cloned based on tetramer binding, and expressed characteristic activation markers upon self-Ag stimulation. These results show that autoreactive T cells are present in most healthy individuals and that Treg likely play an important role of keeping these autoreactive T cells in check.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15128778     DOI: 10.4049/jimmunol.172.10.5967

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  118 in total

1.  HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P.

Authors:  R A Ettinger; E A James; W W Kwok; A R Thompson; K P Pratt
Journal:  Haemophilia       Date:  2010-05       Impact factor: 4.287

Review 2.  New technologies for autoimmune disease monitoring.

Authors:  Holden T Maecker; Garry P Nolan; Charles G Fathman
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-08       Impact factor: 3.243

Review 3.  Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity.

Authors:  Xin Chen; Joost J Oppenheim
Journal:  FEBS Lett       Date:  2011-04-15       Impact factor: 4.124

4.  Re-establishing immunological self-tolerance in autoimmune disease.

Authors:  Shimon Sakaguchi; Fiona Powrie; Richard M Ransohoff
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

5.  microRNAs at the regulatory frontier: an investigation into how microRNAs impact the development and effector functions of CD4 T cells.

Authors:  Erik Allen Lykken; Qi-Jing Li
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

Review 6.  T cell epitopes and post-translationally modified epitopes in type 1 diabetes.

Authors:  John W McGinty; Meghan L Marré; Veronique Bajzik; Jon D Piganelli; Eddie A James
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

7.  Regulatory and T Effector Cells Have Overlapping Low to High Ranges in TCR Affinities for Self during Demyelinating Disease.

Authors:  Jennifer D Hood; Veronika I Zarnitsyna; Cheng Zhu; Brian D Evavold
Journal:  J Immunol       Date:  2015-09-18       Impact factor: 5.422

8.  Single-Cell RNA Sequencing Reveals Expanded Clones of Islet Antigen-Reactive CD4+ T Cells in Peripheral Blood of Subjects with Type 1 Diabetes.

Authors:  Karen Cerosaletti; Fariba Barahmand-Pour-Whitman; Junbao Yang; Hannah A DeBerg; Matthew J Dufort; Sara A Murray; Elisabeth Israelsson; Cate Speake; Vivian H Gersuk; James A Eddy; Helena Reijonen; Carla J Greenbaum; William W Kwok; Erik Wambre; Martin Prlic; Raphael Gottardo; Gerald T Nepom; Peter S Linsley
Journal:  J Immunol       Date:  2017-05-31       Impact factor: 5.422

9.  Increased islet antigen-specific regulatory and effector CD4+ T cells in healthy individuals with the type 1 diabetes-protective haplotype.

Authors:  Xiaomin Wen; Junbao Yang; Eddie James; I-Ting Chow; Helena Reijonen; William W Kwok
Journal:  Sci Immunol       Date:  2020-02-14

Review 10.  To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy.

Authors:  Jessica E Thaxton; Zihai Li
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.